|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Revenue | ||||
| Cost of sales | ||||
| Gross profit | ||||
| Operating expenses: | ||||
| Exploration expenses | ||||
| General and administrative expenses | ||||
| Research and development expenses | ||||
| Selling and marketing expenses | ||||
| Provision expected for credit loss | ||||
| Impairment | ||||
| Loss from operations | ||||
| Other expenses (income): | ||||
| Interest expense, net | ||||
| Foreign exchange loss (gain) | ||||
| Share of losses from significant influence investments | ||||
| Gain on disposal of subsidiary | ||||
| Loss on revaluation of investments, net | ||||
| Loss on revaluation of convertible debt | ||||
| Other expenses (income), net | ||||
| Loss before income taxes | ||||
| Income taxes (recovery) | ||||
| Net loss | ||||
| Other comprehensive loss, net of tax: | ||||
| Foreign currency translation adjustments | ||||
| Other comprehensive loss | ||||
| Comprehensive loss | ||||
| Comprehensive loss attributable to: | ||||
| Common stockholders or parent | ||||
| Non-controlling interests | ||||
| Net loss per share attributable to common stockholders or parent | ||||
| Basic (in USD per share) | ||||
| Diluted (in USD per share) | ||||
| Weighted-average common shares outstanding | ||||
| Basic (in shares) | ||||
| Diluted (in shares) | ||||
| Less loss attributable to non-controlling interests | ||||
| Net loss attributable to common stockholders or parent |
Loading...
